dual agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-20. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Approximate composition of the free peptide |
| Molecular weight | Approximately 4813 Da | Calculated for the free base |
| Structural class | Synthetic linear peptide | 39 residues with modified backbone |
| Solubility | Soluble in water and polar solvents | Behavior of the lyophilized solid |
| Typical storage temperature | -20 degrees Celsius or below | Solid form, protected from light |
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
==== Leukemia ==== The Gβγ subunit has been shown to activate a Rho guanine nucleotide exchange factor (RhoGef) gene PLEKHG2 which is upregulated in a number of leukemia cell lines and mouse models of leukemia. Lymphocyte chemotaxis as a result of Rac and CDC42 activation as well as actin polymerization is believed to be regulated by the Gβγ activated RhoGef. Therefore, a drug inhibiting the Gβγ could play a role in the treatment of leukemia.
delocalized electron Any electron in a molecule, ion, or solid metal that is not associated with an individual atom or covalent bond. The term may refer to electrons involved in resonance in conjugated systems or aromatic compounds; to free electrons which facilitate electrical conductivity; or to electrons within delocalized molecular orbitals encompassing several adjacent atoms.
However, even the smallest proteins have over 1000 atoms, which makes determining their structure far more complex. In 1934, Dorothy Crowfoot Hodgkin had taken crystallographic data on the structure of the small protein, insulin, although the structure of that and other proteins were not solved until the late 1960s. However, pioneering X-ray fiber diffraction data had been collected in the early 1930s for many natural fibrous proteins such as wool and hair by William Astbury, who suggested that "globular proteins in general might be folded from elements essentially like the elements of fibrous proteins." Since protein structure was so poorly understood in the 1930s, the physical interactions responsible for stabilizing that structure were likewise unknown. Astbury hypothesized that the structure of fibrous proteins was stabilized by hydrogen bonds in β-sheets. The idea that globular proteins are also stabilized by hydrogen bonds was proposed by Dorothy Jordan Lloyd in 1932, and championed later by Alfred Mirsky and Linus Pauling. At a 1933 lecture by Astbury to the Oxford Junior Scientific Society, physicist Charles Frank suggested that the fibrous protein α-keratin might be stabilized by an alternative mechanism, namely, covalent crosslinking of the peptide bonds by the cyclol reaction above. The cyclol crosslink draws the two peptide groups close together; the N and C atoms are separated by ~1.5 Å, whereas they are separated by ~3 Å in a typical hydrogen bond. The idea intrigued J. D.
But it was later discovered that this is only true for four of the fifteen lanthanides (lanthanum, cerium, gadolinium, and lutetium), and that the other lanthanide atoms do not have a d-electron. In particular, ytterbium completes the 4f shell and thus Soviet physicists Lev Landau and Evgeny Lifshitz noted in 1948 that lutetium is correctly regarded as a d-block rather than an f-block element; that bulk lanthanum is an f-metal was first suggested by Jun Kondō in 1963, on the grounds of its low-temperature superconductivity. This clarified the importance of looking at low-lying excited states of atoms that can play a role in chemical environments when classifying elements by block and positioning them on the table. Many authors subsequently rediscovered this correction based on physical, chemical, and electronic concerns and applied it to all the relevant elements, thus making group 3 contain scandium, yttrium, lutetium, and lawrencium and having lanthanum through ytterbium and actinium through nobelium as the f-block rows: this corrected version achieves consistency with the Madelung rule and vindicates Bassett, Werner, and Bury's initial chemical placement. In 1988, IUPAC released a report supporting this composition of group 3, a decision that was reaffirmed in 2021.
Sources: en.wikipedia.org
Protein targeting or protein sorting is the biological mechanism by which proteins are transported to their appropriate destinations within or outside the cell. Proteins can be targeted to the inner space of an organelle, different intracellular membranes, the plasma membrane, or to the exterior of the cell via secretion. Information contained in the protein itself directs this delivery process. Correct sorting is crucial for the cell; errors or dysfunction in sorting have been linked to multiple diseases.
A 2003 article said that South Koreans consume 18 kg (40 lbs) of kimchi per person annually. Many credit the Korean Miracle in part to the popularity of the dish. Adult Koreans eat from 50 grams (0.11 lb) to 200 grams (0.44 lb) of kimchi a day.
Belkacem Lounes (Tamazight: Belqasem Lwennas, in Tifinagh: ⴱⴻⵍⴿⴰⵚⴻⵎ ⵍⵓⵏⴻⵙ; born 6 February 1955) is an Algerian Kabyle indigenous politician, economist and activist who served as president of the World Amazigh Congress (CMA) from 2002 to 2011 and later as its secretary general. In October 2025, he was again appointed secretary general of the organization.
== Analysis == When a glucose molecule is to be detected at a certain position in a larger molecule, nuclear magnetic resonance spectroscopy, X-ray crystallography analysis or lectin immunostaining is performed with concanavalin A reporter enzyme conjugate, which binds only glucose or mannose.
==== Statistical factors ==== Statistics from the Tokyo Bureau of Social Welfare and Public Health indicate 20–44 incidents of fugu poisoning per year between 1996 and 2006 in the entire country, leading to 34–64 hospitalizations and 0–6 deaths per year, for an average fatality rate of 6.8%. Of the 23 incidents recorded within Tokyo between 1993 and 2006, only one took place in a restaurant, while the others all involved fishermen eating their catch. From 2006 through 2009 in Japan there were 119 incidents involving 183 people but only seven people died. Only a few cases have been reported in the United States, and outbreaks in countries outside the Indo-Pacific area are rare. In Haiti, tetrodotoxin was thought to have been used in voodoo preparations, in so-called zombie poisons. Subsequent careful analysis has however repeatedly called early studies into question on technical grounds, and failed to identify the toxin in any preparation. Discussion of the matter has therefore all but disappeared from the primary literature since the early 1990s. Kao and Yasumoto concluded in the first of their papers in 1986 that "the widely circulated claim in the lay press to the effect that tetrodotoxin is the causal agent in the initial zombification process is without factual foundation." Genetic background is not a factor in susceptibility to tetrodotoxin poisoning. This toxicosis may be avoided by not consuming animal species known to contain tetrodotoxin, principally pufferfish; other tetrodotoxic species are not usually consumed by humans.
Sources: en.wikipedia.org
=== 7 August === Sudanese prosecutors charged Hemedti and 16 other TASIS leaders with committing war crimes in El Fasher and South Kordofan. Three SLM officials (Legal Advisor Mahmoud Koreina, Economic Affairs Advisor Adam al-Nur, and Media Advisor Mustafa al-Jamil) announced the formation of a splinter faction in Uganda following their dismissal by Minni Minawi. Eighteen people were killed in RSF attacks on the villages of Markaz Al-Ziyadia and Lamina al-Ziyadiyah in North Kordofan.
== History == The sign is named after American physician John Benjamin Murphy (1857–1916), a Chicago surgeon from the 1880s to the early 1900s, who first described the hypersensitivity to deep palpation in the subcostal area when a patient with gallbladder disease takes a deep breath.
=== Alkene === Alkenes rarely need protection or are protected. They are as a rule only involved in undesired side reactions with electrophilic attack, isomerization or catalytic hydration. For alkenes two protecting groups are basically known:
== Synthesis == There is no concrete evidence or agreement on the exact mechanisms of fibrillogenesis, however, multiple hypotheses based on primary research have put forth various mechanisms to consider. Collagen fibrillogenesis occurs in the plasma membrane during embryonic development. Collagen within the body has a denaturation temperature between 32-40 degrees Celsius, the physiological temperature also falls within this range and thereby poses a significant problem. It is not known how collagen survives within the tissues in order to yield itself to the formation of collagen fibrils. A postulated solution to the problem of denaturation, is that newly formed collagen gets stored in vacuoles. The storage vacuoles also contain molecular aggregates that provide the required thermal stability to allow for fibrillogenesis to occur within the body. In the body, fibrillar collagens have over 50 known binding partners. The cell accounts for the variety of binding partners through the localization of the fibrillogenesis process to the plasma membrane in order to maintain control of which molecules bind to each other and further ensure both fibril diversity and assemblies of certain collagen fibrils in different tissues Kader, Hill, and Canty-Larid published a plausible mechanism for the formation of collagen fibrils. Fibronectin a glycoprotein that binds to receptor proteins known as integrins within the cytoskeleton is a key player in the hypothesized method of fibrillogenesis.
Sources: en.wikipedia.org
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.
Single-receptor agents act predominantly at GLP-1R. Tirzepatide retains activity at GIPR, which is expressed in pancreatic islets, adipose tissue, and the central nervous system. The contribution of each receptor to the overall response is still an area of active study, and the relative weight of GIPR signaling in humans is not fully settled.
The fatty diacid moiety binds serum albumin, which reduces renal filtration of the active peptide. Additional resistance to enzymatic breakdown comes from non-natural residues in the backbone. Together these features produce an apparent half-life of about five days and permit weekly dosing intervals.
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.